Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04033497 · ClinicalTrials.gov registry record · NA

Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

A NA study of Brain Tumor, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
101
Enrollment target
2
Study locations

NCT04033497 is a NA study of Brain Tumor that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 101 participants, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04033497, a NA study of Brain Tumor, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
101 participants
Enrollment target
2
Study locations

Study Summary

This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused radiation has enlarged.

Conditions Studied

Interventions

  • DEVICE MRI

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2019-08-20
Est. Completion 2028-07-01
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04033497

The ClinicalTrials.gov registry entry for NCT04033497 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.

NCT04033497 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04033497 about?

NCT04033497 is a clinical study titled "Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases". This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused ra...

What is the current status of trial NCT04033497?

This trial is currently recruiting. It is a NA study. The enrollment target is 101 participants. The study started on 2019-08-20. Estimated completion is 2028-07-01.

What conditions does trial NCT04033497 study?

This clinical trial studies the following conditions: Brain Tumor.

What interventions are being tested in trial NCT04033497?

The interventions under investigation include: MRI (DEVICE).

Who is sponsoring clinical trial NCT04033497?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04033497 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.